Balinatunfib clinical trials
Also written SAR441566.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How each study uses balinatunfib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2023 (4)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Studies
Open first, then newest update. How each study uses balinatunfib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)TerminatedPhase 2SanofiNCT07222189Written as balinatunfib
- A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative ColitisTerminatedPhase 2SanofiNCT06867094Written as SAR441566
- A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.TerminatedPhase 2SanofiNCT06637631Written as SAR441566
- A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.CompletedPhase 1SanofiNCT07272629Written as Balinatunfib
- A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque PsoriasisCompletedPhase 2SanofiNCT06073119Written as SAR441566
- A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate PsoriasisCompletedPhase 1SanofiNCT05453942Written as SAR441566
- A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants.CompletedPhase 1SanofiNCT05858788Written as SAR441566
- A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566CompletedPhase 1SanofiNCT05844735Written as SAR441566
- A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid ArthritisCompletedPhase 2SanofiNCT06073093Written as SAR441566
Codes
What other systems call balinatunfib · ClinicalTrials.gg INT017596
- UNII (FDA) PLY98MAN4CBALINATUNFIBConfirmed FDA, Wikidata
- Wikidata Q133521517balinatunfibConfirmed FDA, Wikidata
- NCI Thesaurus C211795BalinatunfibOne source FDA
- DrugBank DB21728One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | PLY98MAN4C | BALINATUNFIB | Confirmed FDA, Wikidata |
| Wikidata | Q133521517 | balinatunfib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C211795 | Balinatunfib | One source FDA |
| DrugBank | DB21728 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.